Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Blood (2025) 146 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2025-1890

Published: 2025

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Blood (2024) 144 (Supplement 1): 3131.

https://doi.org/10.1182/blood-2024-199720

Published: 2024

Journal Articles

GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

Silvia Ferrari, Anna Maria Barbui, Gritti Giuseppe, Andrea Rossi, Anna Grassi, Francesco Ballardini, Monica Rondi, Chiara Pavoni, Paolo Fruscella, Andrea Gianatti, Alessandro Rambaldi

Blood (2024) 144 (Supplement 1): 3114.

https://doi.org/10.1182/blood-2024-208027

Published: 2024

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

Journal Articles

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Monica Rondi, Silvia Ferrari, Anna Maria Barbui, Andrea Rossi, Chiara Pavoni, Anna Grassi, Federico Lussana, Alessandro Rambaldi, Giuseppe Gritti

Blood (2023) 142 (Supplement 1): 2331.

https://doi.org/10.1182/blood-2023-189911

Published: 2023

Journal Articles

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Blood (2023) 142 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2023-184614

Published: 2023

Journal Articles

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Giuseppe Gritti, Federico Lussana, Silvia Ferrari, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini, Gianmaria Borleri, Muriel Paganessi, Chiara Pavoni, Elisa Gotti, Chiara Capelli, Josee Golay, Martino Introna, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 10325–10326.

https://doi.org/10.1182/blood-2022-170120

Published: 2022

Journal Articles

Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

Blood (2021) 138 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2021-154037

Published: 2021

Journal Articles

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Annalisa Chiappella, Anna Dodero, Anna Guidetti, Filippo Bagnoli, MD, Vanessa Aragona, Anna Maria Barbui, MD, Stefania Bramanti, MD, Matteo Giovanni Carrabba, MD, Federica Sorà, MD, Pierluigi Zinzani, Prof, MD, Chiara Monfrini, Cristiana Carniti, Paolo Corradini

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140054

Published: 2020

Journal Articles

Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy

Giuseppe Gritti, MD, Andrea Gianatti, MD, Fiorella Petronzelli, PhD, Cristina Boschini, BSc, Riccardo Rossi, PhD, Rosangela Trezzi, MD, Andrea Rossi, MD, Anna Maria Barbui, MD, Alessandro Rambaldi, MD

Blood (2016) 128 (22): 4141.

https://doi.org/10.1182/blood.V128.22.4141.4141

Published: 2016

Journal Articles

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Corrado Tarella, MD, Angela Gueli, Federica Delaini, Anna Maria Barbui, MD, Riccardo Bruna, Daniele Caracciolo, Daniela Gottardi, Giuseppe Gritti, MD, Roberto Passera, PharmD, PhD, Safaa Ramadan, PhD MD, Andrea Rossi, MD, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3989.

https://doi.org/10.1182/blood.V126.23.3989.3989

Published: 2015

Journal Articles

Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas

Giuseppe Gritti, MD, Paola Stefanoni, MD, Cristina Boschini, MSc, Andrea Rossi, MD, Anna Maria Barbui, MD, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 4503.

https://doi.org/10.1182/blood.V126.23.4503.4503

Published: 2015

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Transferability Of Results From Randomized Trials To Clinical Practice: The Case Of Diffuse Large B Cell Lymphoma Patients Treated With R-CHOP When Comorbidities Are Present

Anna Maria Barbui, MD, Andrea Rossi, MD, Giuseppe Gritti, MD, Ariel Amaru Calzada, MD PhD, Cristina Boschini, BSc, Federica Delaini, BiolSc, Alessandro Rambaldi, MD

Blood (2013) 122 (21): 4351.

https://doi.org/10.1182/blood.V122.21.4351.4351

Published: 2013

Journal Articles

Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

Blood (2012) 120 (21): 746.

https://doi.org/10.1182/blood.V120.21.746.746

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

GMALL B ALL/NHL 2002 Protocol Yields High Response Rates and Durable Responses in High-Grade B Cell Lymphoma: A Retrospective, Single-Center Study

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem

Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting

Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Transferability Of Results From Randomized Trials To Clinical Practice: The Case Of Diffuse Large B Cell Lymphoma Patients Treated With R-CHOP When Comorbidities Are Present

Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only